Smitha Zaharoff
Clinical Research Institute(US)
Publications by Year
Research Areas
Antibiotics Pharmacokinetics and Efficacy, Antibiotic Resistance in Bacteria, Antimicrobial Resistance in Staphylococcus, Bacterial Identification and Susceptibility Testing, Urinary Tract Infections Management
Most-Cited Works
- → Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial(2022)51 cited
- → Pharmacokinetics of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase 1, Open-Label Study of Healthy Adults(2022)22 cited
- → Safety of Ceftazidime-Avibactam in Combination with Aztreonam (COMBINE) in a Phase I, Open-Label Study in Healthy Adult Volunteers(2022)21 cited
- → Dalbavancin for Treatment of Staphylococcus aureus Bacteremia(2025)19 cited
- → Priorities and Progress in Gram-negative Bacterial Infection Research by the Antibacterial Resistance Leadership Group(2023)17 cited
- → Determination of plasma protein binding of dalbavancin(2022)13 cited
- → The Antibacterial Resistance Leadership Group: Scientific Advancements and Future Directions(2023)9 cited
- → Priorities and Progress in Gram-positive Bacterial Infection Research by the Antibacterial Resistance Leadership Group: A Narrative Review(2023)6 cited
- → 1094. Determination of Plasma Protein Binding of Dalbavancin(2021)1 cited
- → 232. Population Pharmacokinetics (PopPK) of Ceftazidime-Avibactam (CZA) in Combination with Aztreonam (ATM) in a Phase I, Open-Label Study in Healthy Adult Subjects (COMBINE)(2022)